Michael Robert A. 4
4 · AbbVie Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
AbbVie (ABBV) CEO Michael Robert A. Receives 163,690-Share Awards
What Happened
Michael Robert A., CEO of AbbVie, was reported as acquiring a total of 163,690 shares on Feb 18, 2026 through multiple awards (price $0.00). The awards break down as: 33,833 shares, 12,030 shares, 14,452 shares, 22,124 shares, plus a derivative award covering 81,251 shares. The performance-based awards had their vesting conditions certified by AbbVie’s Compensation Committee; the shares will be issued on Feb 28, 2026. The 81,251-share derivative is an employee stock option that vests/exercises in annual increments (27,084 on 2/18/2027, 27,084 on 2/18/2028, 27,083 on 2/18/2029).
Key Details
- Transaction date(s): February 18, 2026 (reported on Form 4 filed Feb 20, 2026). Price: $0.00 (award/grant). Aggregate shares: 163,690.
- Footnotes: F1–F4 = performance-vesting share/RSU awards (granted in 2023–2025) released upon certification of performance goals; F5 = employee stock option under AbbVie’s 2013 Incentive Stock Program.
- Shares issuance: awards to be issued on February 28, 2026.
- Shares owned after transaction: not provided in the excerpt of the filing.
- Filing timeliness: Form 4 filed Feb 20, 2026 for Feb 18, 2026 transactions (appears timely under Section 16 two-business-day rule).
Context
- These were awards/grants (code A) tied to previously granted performance-based awards and an option — not open-market purchases or sales. Awards granted upon certification do not by themselves indicate a buy/sell market signal; they reflect company compensation and performance achievement.
- The derivative item is an option with future exercise dates (2027–2029), not an immediate sale or cashless exercise.
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Michael Robert A.
DirectorCHAIRMAN OF THE BOARD AND CEO
Transactions
- Award
Common Stock, $0.01 par value
[F1]2026-02-18+33,833→ 166,654 total - Award
Common Stock, $0.01 par value
[F2]2026-02-18+12,030→ 178,684 total - Award
Common Stock, $0.01 par value
[F3]2026-02-18+14,452→ 193,136 total - Award
Common Stock, $0.01 par value
[F4]2026-02-18+22,124→ 215,260 total - Award
Option (Right to Buy)
[F5]2026-02-18+81,251→ 81,251 totalExercise: $230.04Exp: 2036-02-17→ Common Stock (81,251 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,084 on February 18, 2027, 27,084 on February 18, 2028, and 27,083 on February 18, 2029.
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Robert A. Michael|2026-02-20